Chesson Labs receives market clearance for Nuvaderm liquid bandage

DURHAM, N.C. Chesson Labs on Wednesday announced receiving 510(k) market clearance from the Food and Drug Administration for its Nuvaderm liquid bandage for use by healthcare professionals or directly to consumers.

The FDA has cleared claims on the product "to cover intact skin and minor cuts, scrapes, burns or irritations of the skin, to help keep them clean and dry and help protect them from infection." The fast application, drying and coverage characteristics make Nuvaderm suited to meet the needs of individuals treating minor wounds, the company stated. The product also has antimicrobial properties.

"Nuvaderm’s clearance is a major milestone for Chesson Labs, but more importantly it is a product developed to improve wound care for individuals treating themselves as well as medical personnel who need a rapid response product to treat minor wounds," stated Scott Neuville, Chesson president and CEO.